Clarity Pharmaceuticals reported an update from the Phase II cohort expansion of its SECuRE trial (NCT04868604) evaluating 67Cu-SAR-bisPSMA in metastatic castration-resistant prostate cancer. The company said another participant receiving 8 GBq per cycle achieved undetectable PSA after the first cycle and had a negative PSMA PET scan after the second cycle; related adverse events were Grade 1 and no hematological or renal adverse events were observed to date. Clarity stated this is the fifth patient with undetectable disease by radiographic assessment following 67Cu-SAR-bisPSMA treatment, and also provided follow-up that a previously reported participant remains undetectable on PSMA PET one month after a fourth cycle. The results were presented in this announcement, and the SECuRE trial is continuing enrollment with planned recruitment completion in 2026 while Phase III planning is ongoing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clarity Pharmaceuticals Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN92976) on February 23, 2026, and is solely responsible for the information contained therein.